Next Article in Journal
Thiazole-Bearing 4-Thiazolidinones as New Anticonvulsant Agents
Previous Article in Journal
P-Glycoprotein/ABCB1 Might Contribute to Morphine/Cisplatin-Induced Hepatotoxicity in Rats
Open AccessArticle

Development and Evaluation of Curcumin Liquid Crystal Systems for Cervical Cancer

1
PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, Bandar Seri Begawan BE1410, Brunei
2
School of Pharmacy, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, Kuala Lumpur 57000, Malaysia
3
School of Health Sciences, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, Kuala Lumpur 57000, Malaysia
4
Institute of Pharmacy, Jalpaiguri, Govt. of West Bengal, West Bengal 735101, India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2020, 88(1), 15; https://doi.org/10.3390/scipharm88010015
Received: 19 February 2020 / Revised: 14 March 2020 / Accepted: 17 March 2020 / Published: 23 March 2020
Curcumin is a hydrophobic compound with good anti-proliferative, anti-oxidative, and anti-cancer properties but has poor bioavailability. Liquid crystals (LC) can accommodate both hydrophilic and hydrophobic drugs. The aim of this study was to formulate and evaluate a novel vaginal drug delivery system for cervical cancer using a curcumin LC system. The curcumin LC system was formulated using surfactant, glycerol, and water together with curcumin. Three types of surfactants were used to optimize the formulation, i.e., Tween 80, Cremphor EL, and Labrasol. The optimized formulations were subjected to physicochemical analysis, and their efficacy was evaluated in HeLa cells. The pH of the formulations was in the range of 3.91–4.39. Environmental scanning electron microscopy (ESEM) observations revealed spherical as well as hexagonal micelles. In vitro release of LC curcumin from vaginal simulated fluid (VSF, pH 4.5) showed a release from 20.47% to 87.25%. The IC50 of curcumin in HeLa cells was 22.5 μg/mL, while the IC25 and IC75 were 6.5 μg/mL and 35μg/mL, respectively. The cytotoxicity of the formulations was determined in comparison with liquid crystals without curcumin and pure curcumin by performing a t-test based on a significance level of p less than or equal to 0.05 (p ≤ 0.05). The curcumin LC system was able to release the required amount of drug and was effective against the cervical cancer cell line examined. View Full-Text
Keywords: cervical cancer; liquid crystal; curcumin; HeLa cells cervical cancer; liquid crystal; curcumin; HeLa cells
Show Figures

Figure 1

MDPI and ACS Style

R David, S.; Akmar Binti Anwar, N.; Yian, K.R.; Mai, C.-W.; Das, S.K.; Rajabalaya, R. Development and Evaluation of Curcumin Liquid Crystal Systems for Cervical Cancer. Sci. Pharm. 2020, 88, 15.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop